Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_182593
Pages: 196
Jan 2018 | 2266 Views
face gplus_n
Author's : Tenzin Kunsel and Onkar Sumant
Tables: 80
Charts: 47
twit_n pr_n

Antidepressant Drugs Market Overview:

Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression. According to WHO almost 350 million people worldwide were affected with depression in 2016. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps in the treatment of depression. The global antidepressant drugs market was valued at $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023.

Increase in prevalence of depression, rise in geriatric population, and emergence of novel techniques for the development of drugs with fewer side-effects drive the market. Moreover, increase in awareness regarding the disease state and required clinical needs, and rise in number of people suffering from stress can fuel the growth of the antidepressant drugs market. However, poor efficacy and safety profiles of the drug, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

Depressive Disorder Segment Review

Based on depressive disorder, it is categorized into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. Major depressive disorder is the largest contributor toward the market growth as majority of the people are usually diagnosed with this disorder due to increase in stress levels. However, obsessive-compulsive disorder is the fastest growing segment.

Product Segment Review

Based on product, it is segmented into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others. Selective serotonin reuptake inhibitors is the dominant segment owing to the presence of large number of these drugs.

Global Antidepressant Drugs Market: Key Geographic Segment

Based on region, the antidepressant drugs market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the antidepressant drugs market in 2016, and is expected to retain its dominance throughout the forecast period.

The key players operating in the global antidepressant drugs market include Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Other prominent players in the value chain include Opko Health, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Novartis, Forest Laboratories, and AstraZeneca.

Key Benefits for Stakeholders

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Antidepressant Drugs Market Key Segments:

By Depression Disorder

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

By Product

  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine reuptake Inhibitors
  • Monoamine oxidase inhibitors
  • Serotonin antagonist and reuptake inhibitors
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1: INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3: MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies

3.3. MARKET SHARE ANALYSIS
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in Prevalence of Depression
3.5.1.2. Rise in Geriatric Population
3.5.1.3. Increase in Awareness

3.5.2. Restrains

3.5.2.1. Non-Pharmacological Therapies Preferred Over Pharmacological Therapies
3.5.2.2. Poor Efficacy and Safety Profiles
3.5.2.3. Patent Expiry of Antidepressants leading to Weak Pipeline

3.5.3. Opportunities

3.5.3.1. Emergence of Novel Multimodal Therapies

Chapter: 4: ANTIDEPRESSANT DRUGS MARKET BY DEPRESSIVE DISORDER

4.1. OVERVIEW

4.1.1. Market Size and Forecast

4.2. MAJOR DEPRESSIVE DISORDER

4.2.1. Key Market Trends & Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Size and Forecast, by Country

4.3. OBSESSIVE-COMPULSIVE DISORDER

4.3.1. Key Market Trends & Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Size and Forecast, by Country

4.4. GENERALIZED ANXIETY DISORDER

4.4.1. Key Market Trends & Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Size and Forecast, by Country

4.5. PANIC DISORDER

4.5.1. Key Market Trends & Opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Size and Forecast, by Country

4.6. OTHERS

4.6.1. Key Market Trends & Opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Size and Forecast, by Country

Chapter: 5: ANTIDEPRESSANT DRUGS MARKET BY PRODUCT TYPE

5.1. OVERVIEW

5.1.1. Market Size and Forecast

5.2. TRICYCLIC ANTIDEPRESSANTS

5.2.1. Market Size and Forecast
5.2.2. Market Size and Forecast, by Country

5.3. SELECTIVE SEROTONIN REUPTAKE INHIBITORS

5.3.1. Market Size and Forecast
5.3.2. Market Size and Forecast, by Country

5.4. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS

5.4.1. Market Size and Forecast
5.4.2. Market Size and Forecast, by Country

5.5. MONOAMINE OXIDASE INHIBITORS

5.5.1. Market Size and Forecast
5.5.2. Market Size and Forecast, by Country

5.6. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS

5.6.1. Market Size and Forecast
5.6.2. Market Size and Forecast, by Country

5.7. OTHERS

5.7.1. Market Size and Forecast
5.7.2. Market Size and Forecast, by Country

Chapter: 6: ANTIDEPRESSANT DRUGS MARKET BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market Size and Forecast

6.2. NORTH AMERICA

6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Depressive Disorder
6.2.3. Market Size and Forecast, by Product Type
6.2.4. Market Size and Forecast, by Country

6.2.4.1. U.S. Market Size and Forecast, by Depressive Disorder
6.2.4.2. U.S. Market Size and Forecast, by Product Type
6.2.4.3. Canada Market Size and Forecast, by Depressive Disorder
6.2.4.4. Canada Market Size and Forecast, by Product Type
6.2.4.5. Mexico Market Size and Forecast, by Depressive Disorder
6.2.4.6. Mexico Market Size and Forecast, by Product Type

6.3. EUROPE

6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Depressive Disorder
6.3.3. Market Size and Forecast, by Product Type
6.3.4. Market Size and Forecast, by Country

6.3.4.1. Germany Market Size and Forecast, by Depressive Disorder
6.3.4.2. Germany Market Size and Forecast, by Product Type
6.3.4.3. France Market Size and Forecast, by Depressive Disorder
6.3.4.4. France Market Size and Forecast, by Product Type
6.3.4.5. UK Market Size and Forecast, by Depressive Disorder
6.3.4.6. UK Market Size and Forecast, by Product Type
6.3.4.7. Italy Market Size and Forecast, by Depressive Disorder
6.3.4.8. Italy Market Size and Forecast, by Product Type
6.3.4.9. Spain Market Size and Forecast, by Depressive Disorder
6.3.4.10. Spain Market Size and Forecast, by Product Type
6.3.4.11. Rest of Europe Market Size and Forecast, by Depressive Disorder
6.3.4.12. Rest of Europe Market Size and Forecast, by Product Type

6.4. ASIA-PACIFIC

6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Depressive Disorder
6.4.3. Market Size and Forecast, by Product Type
6.4.4. Market Size and Forecast, by Country

6.4.4.1. Japan Market Size and Forecast, by Depressive Disorder
6.4.4.2. Japan Market Size and Forecast, by Product Type
6.4.4.3. China Market Size and Forecast, by Depressive Disorder
6.4.4.4. China Market Size and Forecast, by Product Type
6.4.4.5. Australia Market Size and Forecast, by Depressive Disorder
6.4.4.6. Australia Market Size and Forecast, by Product Type
6.4.4.7. India Market Size and Forecast, by Depressive Disorder
6.4.4.8. India Market Size and Forecast, by Product Type
6.4.4.9. South Korea Market Size and Forecast, by Depressive Disorder
6.4.4.10. South Korea Market Size and Forecast, by Product Type
6.4.4.11. Rest of Asia-Pacific Market Size and Forecast, by Depressive Disorder
6.4.4.12. Rest of Asia-Pacific Market Size and Forecast, by Product Type

6.5. LAMEA

6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Depressive Disorder
6.5.3. Market Size and Forecast, by Product Type
6.5.4. Market Size and Forecast, by Country

6.5.4.1. Brazil Market Size and Forecast, by Depressive Disorder
6.5.4.2. Brazil Market Size and Forecast, by Product Type
6.5.4.3. Saudi Arabia Market Size and Forecast, by Depressive Disorder
6.5.4.4. Saudi Arabia Market Size and Forecast, by Product Type
6.5.4.5. South Africa Market Size and Forecast, by Depressive Disorder
6.5.4.6. South Africa Market Size and Forecast, by Product Type
6.5.4.7. Rest of LAMEA Market Size and Forecast, by Depressive Disorder
6.5.4.8. Rest of LAMEA Market Size and Forecast, by Product Type

Chapter: 7: COMPANY PROFILES

7.1. ALKERMES PLC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance

7.2. ALLERGAN PLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. BRISTOL MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Business performance

7.4. ELI LILLY AND COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance

7.5. GLAXOSMITHKLINE INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance

7.6. H. LUNDBECK A/S

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Business performance
7.6.4. Key strategic moves and developments

7.7. MERCK INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance

7.8. PFIZER INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance

7.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance

7.10. TAKEDA PHARMACEUTICAL INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Business performance

LIST OF TABLES

TABLE 01. GLOBAL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 02. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 03. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 04. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 05. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR PANIC DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 06. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR OTHER DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 07. GLOBAL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 08. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 09. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 10. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR OTHER PRODUCT TYPE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 14. ANTIDEPRESSANT DRUGS MARKET REVENUE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. NORTH AMERICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18. U.S. ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 19. U.S. ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 20. CANADA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 21. CANADA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 22. MEXICO ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 23. MEXICO ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 24. EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 25. EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 26. EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. GERMANY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 28. GERMANY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 29. FRANCE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 30. FRANCE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 31. UK ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 32. UK ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 33. ITALY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 34. ITALY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 35. SPAIN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 36. SPAIN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 37. REST OF EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 38. REST OF EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 39. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 41. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. JAPAN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 43. JAPAN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44. CHINA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 45. CHINA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 46. AUSTRALIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 47. AUSTRALIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 48. INDIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 49. INDIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 50. SOUTH KOREA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 51. SOUTH KOREA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 54. LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 55. LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. BRAZIL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 58. BRAZIL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 59. SAUDI ARABIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 61. SOUTH AFRICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 62. SOUTH AFRICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 64. REST OF LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 65. ALKERMES: COMPANY SNAPSHOT
TABLE 66. ALLERGAN: COMPANY SNAPSHOT
TABLE 67. ALLERGAN: OPERATING SEGMENTS
TABLE 68. BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 69. LILLY: COMPANY SNAPSHOT
TABLE 70. LILLY: OPERATING SEGMENTS
TABLE 71. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 72. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 73. LUNDBECK: COMPANY SNAPSHOT
TABLE 74. MERCK: COMPANY SNAPSHOT
TABLE 75. MERCK: OPERATING SEGMENTS
TABLE 76. PFIZER: COMPANY SNAPSHOT
TABLE 77. PFIZER: OPERATING SEGMENTS
TABLE 78. SAGE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 79. TEVA: OPERATING SEGMENTS
TABLE 80. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 01. GLOBAL ANTIDEPRESSANT DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 04. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 05. MARKET SHARE ANALYSIS, 2016
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. BARGAINING POWER OF SUPPLIERS
FIGURE 08. THREAT OF NEW ENTRANTS
FIGURE 09. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR OTHER DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR OTHER PRODUCT TYPE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 22. ALKERMES: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ALKERMES: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ALKERMES: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. BRISTOL MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. BRISTOL MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 29. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. GLAXOSMITHKLINE: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. LUNDBECK: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. LUNDBECK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 42. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 45. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 46. TAKEDA PHARMACEUTICAL: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. TAKEDA PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

The advancements regarding development of latest molecules and emergence of novel therapies such as multi-modal therapy are expected to boost the market growth. Such novel therapies have shown positive results for the treatment of depression during clinical studies and cause fewer side-effects. The discovery of new potential medications for the patients suffering from depression has increased over the years. According to American Psychiatric Association antidepressant drugs are one of the most commonly used drug classes in the U.S., and the uptake of the same has increased among the youth in the recent years.

The key factors that have propelled the market growth include the increase in prevalence of depression, along with the increase in geriatric population across the globe. In addition, emergence of novel techniques for the development of drugs with fewer side-effects is expected to boost the market growth. Moreover, increase in awareness regarding the disease as well as required clinical needs, and rise in number of people suffering from stress is expected to fuel the growth of the antidepressant drugs market. However, poor efficacy and safety profiles of the drug, preference for non-pharmacological therapies, along with increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

The use of antidepressants is the highest in North America, particularly in the U.S., owing to the high prevalence rate of depression, increase in disposable income among customers, and emergence of novel therapies that cause fewer side-effects. Although the use of gene therapy in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, rise in incidence rate of depression, and large number of geriatric population, which are projected to fuel the market growth.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Antidepressant Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts